Board Change • Aug 10
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 6 experienced directors. 3 highly experienced directors. 3 independent directors (7 non-independent directors). Independent Outside Director Makiko Shinoda was the last independent director to join the board, commencing their role in 2026. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Anuncio • Aug 07
M3, Inc. Provides Consolidated Earnings Guidance for the six Months Ending September 30, 2026 and Fiscal Year Ending March 31, 2027 M3, Inc. provided consolidated earnings guidance for the six months ending September 30, 2026 and fiscal year ending March 31, 2027. For the six months, the company expects revenue of JPY 192,000 million, operating profit of JPY 37,000 million, profit of JPY 26,000 million, profit attributable to owners of the parent of JPY 24,000 million, and basic earnings per share of JPY 35.45.
For the fiscal year, the company expects revenue of JPY 400,000 million, operating profit of JPY 80,000 million, profit of JPY 56,000 million, profit attributable to owners of the parent of JPY 53,000 million, and basic earnings per share of JPY 78.29. Anuncio • Jun 09
M3, Inc. to Report Q1, 2027 Results on Aug 06, 2026 M3, Inc. announced that they will report Q1, 2027 results on Aug 06, 2026 Anuncio • Jun 05
M3, Inc. (TSE:2413) signed Share Transfer Agreement to acquire Wiseman Co. Ltd from Soichiro Minamidate and MMK GK. M3, Inc. (TSE:2413) signed Share Transfer Agreement to acquire Wiseman Co. Ltd from Soichiro Minamidate and MMK GK on June 5, 2026.
For the period ending June 30, 2025, Wiseman Co. Ltd reported total revenue of ¥12.38 billion, operating loss of ¥222 million and net loss of ¥170 million. As of June 30, 2025, Wiseman Co. Ltd reported total assets of ¥20.03 billion and total common equity of ¥2.74 billion.
The expected completion of the transaction is July 1, 2026. Anuncio • May 02
M3, Inc., Annual General Meeting, Jun 26, 2026 M3, Inc., Annual General Meeting, Jun 26, 2026. Anuncio • Apr 22
M3, Inc. to Report Fiscal Year 2026 Results on May 01, 2026 M3, Inc. announced that they will report fiscal year 2026 results on May 01, 2026 Anuncio • Nov 29
M3, Inc. to Report Q3, 2026 Results on Feb 04, 2026 M3, Inc. announced that they will report Q3, 2026 results on Feb 04, 2026 Board Change • Nov 24
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 7 non-independent directors. Independent Outside Director Satoko Suzuki was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Anuncio • Sep 04
Intermestic Inc. (TSE:262A) agreed to acquire Horus Co., Ltd. from M3, Inc. (TSE:2413), NIC Fund II Cayman, LP, Camellia Fund 2 Cayman L.P., Kerasus Fund 2 Cayman L.P., Wisteria Fund II Cayman, LP and Horus IE Limited Liability Partnership for ¥19.1 billion. Intermestic Inc. (TSE:262A) agreed to acquire Horus Co., Ltd. from M3, Inc. (TSE:2413), NIC Fund II Cayman, LP, Camellia Fund 2 Cayman L.P., Kerasus Fund 2 Cayman L.P., Wisteria Fund II Cayman, LP and Horus IE Limited Liability Partnership for ¥19.1 billion on September 2, 2025. A cash consideration of ¥19.08 billion will be paid by Intermestic Inc. As part of consideration, ¥19.08 billion is paid towards common equity of Horus Co., Ltd. The transaction will be financed through senior debt of ¥18 billion.
For the period ending April 30, 2025, Horus Co., Ltd. reported total revenue of ¥28.19 billion and EBIT of ¥1.84 billion. As of April 30, 2025, Horus Co., Ltd. reported total assets of ¥19.95 billion and total common equity of ¥4.42 billion.
The expected completion of the transaction is October 1, 2025. Anuncio • Sep 01
M3, Inc. to Report Q2, 2026 Results on Nov 12, 2025 M3, Inc. announced that they will report Q2, 2026 results on Nov 12, 2025 Anuncio • Jun 05
EUCALIA Inc. (TSE:286A) signed an agreement to acquire Epigno Inc. from a group of shareholders. EUCALIA Inc. (TSE:286A) signed an agreement to acquire Epigno Inc. from a group of shareholders on June 5, 2025. EUCALIA Inc acquired 0.053 shares in Epigno Inc. The sellers were 19.9% stake from M3, Inc., 9.4% stake from M3 Career, Inc., 11.7% stake from THVP-No. 1 Limited Partnership, a fund managed by Tohoku University Venture Partners Co.,Ltd., 22.5% stake from Fumiyoshi Inui,12.1% stake from Takuya Shiga. The other sellers were Lifetime Ventures Investment LP, Kanshin Mirai No.2 Investment LP, Healthcare New Frontier Investment LP, and Colopl Next No.7 Fund Investment LP.
For the period ending August 31, 2024, Epigno Inc. reported total revenue of approximately ¥110 million, operating loss of ¥83.7 million, net loss of ¥81.19 million, total assets of approximately ¥190 million and net assets of ¥23.3 million. The transaction is expected to close on July 1, 2025. Anuncio • May 31
M3, Inc. to Report Q1, 2026 Results on Aug 06, 2025 M3, Inc. announced that they will report Q1, 2026 results on Aug 06, 2025 Anuncio • May 03
M3, Inc. (TSE:2413) announces an Equity Buyback for 20,000,000 shares, representing 2.95% for ¥20,000 million. M3, Inc. (TSE:2413) announces a share repurchase program. Under the program, the company will repurchase up to 20,000,000 shares, representing 2.95% of its total shares outstanding (excluding treasury shares), for a total of ¥20,000 million. The purpose of repurchase program is to provide returns to shareholders. The repurchase program is valid till April 30, 2026. As of March 31, 2025, the company had 679,032,629 shares issued (excluding treasury shares) and 45,271 treasury shares Valuation Update With 7 Day Price Move • Apr 09
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to €9.30, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 18x in the Healthcare Services industry in Europe. Total loss to shareholders of 70% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €10.96 per share. Board Change • Apr 07
Less than half of directors are independent There are 6 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 2 independent directors. 9 non-independent directors. Independent Outside Director Satoko Suzuki was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Valuation Update With 7 Day Price Move • Mar 18
Investor sentiment improves as stock rises 25% After last week's 25% share price gain to €11.40, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 20x in the Healthcare Services industry in Europe. Total loss to shareholders of 8.6% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €13.87 per share. Board Change • Mar 18
Less than half of directors are independent There are 6 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 2 independent directors. 9 non-independent directors. Independent Outside Director Satoko Suzuki was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Anuncio • Mar 07
M3, Inc. (TSE:2413) entered into Share transfer agreement to acquire 51% stake in Ewel Inc. from Tokyu Land Corporation for ¥10.2 billion. M3, Inc. (TSE:2413) agreed to acquire 51% stake in Ewel Inc. from Tokyu Land Corporation for ¥10.2 billion on March 5, 2025. A cash consideration of ¥10.2 billion will be paid by M3, Inc. As part of consideration, ¥10.2 billion is paid towards common equity of Ewel Inc. The transaction will be financed through Cash on Hand of ¥10.2 billion.
For the period ending March 31, 2024, Ewel Inc. reported total revenue of ¥11.67 billion, EBIT of ¥887 million and net income of ¥566 million. As of March 31, 2024, Ewel Inc. reported total assets of ¥13.65 billion and total common equity of ¥5.88 billion.
The expected completion of the transaction is April 1, 2025. Anuncio • Mar 01
M3, Inc. to Report Fiscal Year 2025 Results on May 02, 2025 M3, Inc. announced that they will report fiscal year 2025 results on May 02, 2025 Anuncio • Feb 10
M3, Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2025 M3, Inc. provided consolidated earnings guidance for the fiscal year ending March 31, 2025. For the period, the company expected revenue to be in the range of JPY 268,000 million to JPY 273,000 million, operating profit to be in the range of JPY 67,000 million to JPY 70,000 million, profit attributable to owners of the parent to be in the range of JPY 44,000 million to JPY 46,000 million and basic earnings per share to be in the range of JPY 64.80 to JPY 67.75. Anuncio • Nov 30
M3, Inc. to Report Q3, 2025 Results on Feb 10, 2025 M3, Inc. announced that they will report Q3, 2025 results on Feb 10, 2025 Reported Earnings • Nov 01
Second quarter 2025 earnings released: EPS: JP¥8.90 (vs JP¥16.19 in 2Q 2024) Second quarter 2025 results: EPS: JP¥8.90 (down from JP¥16.19 in 2Q 2024). Revenue: JP¥60.6b (up 3.8% from 2Q 2024). Net income: JP¥6.05b (down 45% from 2Q 2024). Profit margin: 10.0% (down from 19% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Healthcare Services industry in Europe. Board Change • Sep 24
Less than half of directors are independent There are 6 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 2 independent directors. 10 non-independent directors. Independent Outside Director Satoko Suzuki was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Anuncio • Aug 27
M3, Inc. to Report Q2, 2025 Results on Oct 30, 2024 M3, Inc. announced that they will report Q2, 2025 results on Oct 30, 2024 Board Change • Jun 10
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 1 independent director. 11 non-independent directors. Independent External Director Yusuke Tsugawa was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Anuncio • Jun 03
M3, Inc. to Report Q1, 2025 Results on Jul 26, 2024 M3, Inc. announced that they will report Q1, 2025 results on Jul 26, 2024 Valuation Update With 7 Day Price Move • May 03
Investor sentiment deteriorates as stock falls 21% After last week's 21% share price decline to €10.00, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 23x in the Healthcare Services industry in Europe. Reported Earnings • May 02
Full year 2024 earnings released: EPS: JP¥66.68 (vs JP¥72.22 in FY 2023) Full year 2024 results: EPS: JP¥66.68 (down from JP¥72.22 in FY 2023). Revenue: JP¥238.9b (up 3.5% from FY 2023). Net income: JP¥45.3b (down 7.7% from FY 2023). Profit margin: 19% (down from 21% in FY 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.4% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Healthcare Services industry in Europe. Board Change • May 02
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 1 independent director. 11 non-independent directors. Independent External Director Yusuke Tsugawa was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Upcoming Dividend • Mar 21
Upcoming dividend of JP¥21.00 per share Eligible shareholders must have bought the stock before 28 March 2024. Payment date: 12 June 2024. Payout ratio is a comfortable 28% and this is well supported by cash flows. Trailing yield: 0.9%. Lower than top quartile of German dividend payers (4.9%). Lower than average of industry peers (1.5%). Board Change • Mar 11
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 1 independent director. 11 non-independent directors. Independent External Director Yusuke Tsugawa was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Anuncio • Mar 02
M3, Inc. to Report Fiscal Year 2024 Results on Apr 26, 2024 M3, Inc. announced that they will report fiscal year 2024 results on Apr 26, 2024 Reported Earnings • Feb 02
Third quarter 2024 earnings released: EPS: JP¥19.45 (vs JP¥22.42 in 3Q 2023) Third quarter 2024 results: EPS: JP¥19.45 (down from JP¥22.42 in 3Q 2023). Revenue: JP¥63.4b (up 1.4% from 3Q 2023). Net income: JP¥13.2b (down 13% from 3Q 2023). Profit margin: 21% (down from 24% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 8.7% growth forecast for the Healthcare Services industry in Europe. Board Change • Dec 11
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 1 independent director. 11 non-independent directors. Independent External Director Yusuke Tsugawa was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Anuncio • Nov 29
M3, Inc. to Report Q3, 2024 Results on Jan 31, 2024 M3, Inc. announced that they will report Q3, 2024 results on Jan 31, 2024 Anuncio • Nov 16
M3, Inc. (TSE:2413) entered into a share tender agreement to acquire a 55% stake in Benefit One Inc. (TSE:2412) from Pasona Group Inc. (TSE:2168) and others for approximately ¥140 billion. M3, Inc. (TSE:2413) entered into a share tender agreement to acquire a 55% stake in Benefit One Inc. (TSE:2412) from Pasona Group Inc. (TSE:2168) and others for approximately ¥140 billion on November 14, 2023. The offer price is ¥1600 cash per share. The transaction is subject to minimum tender of 81,210,400 shares and maximum of 87,307,300 shares. The offer period will commence on November 15, 2023 and end on December 13, 2023. Reported Earnings • Oct 30
Second quarter 2024 earnings released: EPS: JP¥18.51 (vs JP¥17.58 in 2Q 2023) Second quarter 2024 results: EPS: JP¥18.51 (up from JP¥17.58 in 2Q 2023). Revenue: JP¥57.9b (up 4.1% from 2Q 2023). Net income: JP¥12.6b (up 5.3% from 2Q 2023). Profit margin: 22% (in line with 2Q 2023). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 7.4% growth forecast for the Healthcare Services industry in Europe. Anuncio • Oct 29
M3, Inc. Provides Consolidated Earnings Guidance for the Full Fiscal Year Ending March 31, 2024 M3, Inc. provided Consolidated earnings guidance for the full Fiscal Year Ending March 31, 2024. For the year, company expects Net sales of JPY 250,000 million, Operating profit of JPY 75,000 million, Net profit of JPY 52,000 million, Net profit attributable to owners of the parent of JPY 50,000 million and Basic earnings per share of JPY 73.65. Board Change • Oct 18
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 1 independent director. 11 non-independent directors. Independent External Director Yusuke Tsugawa was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Anuncio • Aug 30
M3, Inc. to Report Q2, 2024 Results on Oct 27, 2023 M3, Inc. announced that they will report Q2, 2024 results on Oct 27, 2023 Anuncio • Aug 22
M3, Inc. (TSE:2413) acquired Messly Limited. M3, Inc. (TSE:2413) acquired Messly Limited on August 21, 2023.M3, Inc. (TSE:2413) completed the acquisition of Messly Limited on August 21, 2023. Anuncio • Aug 08
M3, Inc. (TSE:2413) acquired frogwell corporation. M3, Inc. (TSE:2413) acquired frogwell corporation on August 7, 2023.M3, Inc. (TSE:2413) completed the acquisition of frogwell corporation on August 7, 2023. Anuncio • Jul 30
M3, Inc. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2023 and the Full Year Ending March 31, 2024 M3, Inc. provided consolidated earnings guidance for the six months ending September 30, 2023 and the full year ending March 31, 2024. For the six months ending September 30, 2023, the company expects net sales of ¥120,000 million, Operating profit of ¥32,000 million and Net profit of ¥22,200 million or ¥31.37 basic per share. The company expects profit attributable to owners of the parent company of ¥21,300 million.For the year ending March 31, 2024, the company expects net sales of ¥250,000 million, Operating profit of ¥75,000 million and Net profit of ¥52,000 million or ¥73.65 basic per share. The company expects profit attributable to owners of the parent company of ¥50,000 million. New Risk • Jun 23
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 21% Last year net profit margin: 31% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risk Profit margins are more than 30% lower than last year (21% net profit margin). Board Change • Jun 23
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Director Rie Nakamura was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Anuncio • May 28
M3, Inc. to Report Q1, 2024 Results on Jul 28, 2023 M3, Inc. announced that they will report Q1, 2024 results on Jul 28, 2023 Anuncio • Feb 04
M3, Inc. (TSE:2413) acquired Michael Allen Company. M3, Inc. (TSE:2413) acquired Michael Allen Company on February 3, 2023.M3, Inc. (TSE:2413) completed the acquisition of Michael Allen Company on February 3, 2023. Anuncio • Nov 24
M3, Inc. to Report Q3, 2023 Results on Feb 03, 2023 M3, Inc. announced that they will report Q3, 2023 results on Feb 03, 2023 Anuncio • Sep 30
M3, Inc. (TSE:2413) acquired Rinkai Medical Service. M3, Inc. (TSE:2413) acquired Rinkai Medical Service on September 28, 2022.
M3, Inc. (TSE:2413) completed the acquisition of Rinkai Medical Service on September 28, 2022. Anuncio • Aug 25
M3, Inc. to Report Q2, 2023 Results on Nov 02, 2022 M3, Inc. announced that they will report Q2, 2023 results on Nov 02, 2022 Reported Earnings • Jul 28
First quarter 2023 earnings released: EPS: JP¥19.87 (vs JP¥23.23 in 1Q 2022) First quarter 2023 results: EPS: JP¥19.87 (down from JP¥23.23 in 1Q 2022). Revenue: JP¥57.0b (up 23% from 1Q 2022). Net income: JP¥13.5b (down 14% from 1Q 2022). Profit margin: 24% (down from 34% in 1Q 2022). Over the next year, revenue is forecast to grow 10%, compared to a 16% growth forecast for the industry in Germany. Board Change • Jul 13
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Director Rie Nakamura was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Anuncio • Jun 09
M3, Inc. (TSE:2413) acquired Edoctores Soluciones. M3, Inc. (TSE:2413) acquired Edoctores Soluciones on June 8, 2022.
M3, Inc. (TSE:2413) completed the acquisition of Edoctores Soluciones on June 8, 2022. Anuncio • May 25
M3, Inc. to Report Q1, 2023 Results on Jul 27, 2022 M3, Inc. announced that they will report Q1, 2023 results on Jul 27, 2022 Board Change • May 12
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 3 highly experienced directors. No independent directors (6 non-independent directors). Director Kazuyuki Izumiya was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Anuncio • Apr 28
M3, Inc. Announces Dividend for the Year Ended March 31, 2022, Payable on June 13, 2022 M3, Inc. announced a dividend of ¥16.00 per share for the year ended March 31, 2022 against ¥12.00 per share paid a year ago. Dividend payment commencement date is on June 13, 2022. Anuncio • Apr 07
M3, Inc. to Report Q4, 2022 Results on Apr 27, 2022 M3, Inc. announced that they will report Q4, 2022 results on Apr 27, 2022 Board Change • Mar 28
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 3 highly experienced directors. Director Kazuyuki Izumiya was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. 
